Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Checkpoint Therapeutics, Inc. Common Stock (CKPT)

Pharmaceutical Preparations

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

95 SAWYER ROAD, SUITE 110
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/02/2016

Market Cap

98,385,516

Shares Outstanding

22,830,000

Weighted SO

23,526,035

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

MBIO --.--%

MBIO --.--%

RVPH --.--%

RVPH --.--%

FBIOP --.--%

KOD --.--%

FBIO --.--%

ATXI --.--%

PIRS --.--%

Beta

1.2520

Last Div

0.0000

Range

1.3-3.62

Chg

-0.0100

Avg Vol

405924

Mkt Cap

98385516

Exch

NASDAQ

Country

US

Phone

781 652 4500

DCF Diff

1.9441

DCF

0.2559

Div Yield

0.0000

P/S

1261.3528

EV Multiple

-2.6326

P/FV

-5.1488

Div Yield %

0.0000

P/E

-1.9094

PEG

-0.0301

Payout

0.0000

Current Ratio

0.2647

Quick Ratio

0.2647

Cash Ratio

0.2311

DSO

191.8590

DIO

0.0000

Op Cycle

191.8590

DPO

229.5741

CCC

-37.7151

Gross Margin

-284.7949

Op Margin

-455.0128

Pretax Margin

-544.4487

Net Margin

-544.4487

Eff Tax Rate

-0.1789

ROA

-7.4898

ROE

2.9243

ROCE

2.2535

NI/EBT

1.0000

EBT/EBIT

1.1966

EBIT/Rev

-455.0128

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-4.6643

CF/Debt

0.0000

Equity Multi

-0.3600

Rec Turnover

1.9024

Pay Turnover

1.5899

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0138

OCF/Share

-0.9390

FCF/Share

-0.9390

Cash/Share

0.1355

OCF/Sales

-439.7051

FCF/OCF

1.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

-5.1488

P/B

-5.1488

P/S

1261.3528

P/E

-1.9094

P/FCF

-2.8686

P/OCF

-2.3643

P/CF

-2.3643

PEG

-0.0301

P/S

1261.3528

EV Multiple

-2.6326

P/FV

-5.1488

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Mar 11, 01:04 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CKPT, RDFN, BLBX on Behalf of Shareholders GlobeNewswire Inc. Dec 13, 23:15 Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) Benzinga Dec 19, 13:34 Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session PennyStocks Dec 06, 14:48 Best Penny Stocks To Buy? 4 To Watch With Big News This Week PennyStocks Dec 06, 14:48 Best Penny Stocks To Buy? 4 To Watch With Big News This Week

Revenue Product Segmentation